PolarityTE, Inc. (NASDAQ:PTE) is set to announce third quarter earning results on Monday 9th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, PTE to report 3Q20 loss of $ 0.21 per share.
For the full year, analysts anticipate top line of $ 9.34 million, while looking forward to loss of $ 0.99 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 3.20 million ~ $ 3.20 million
Click Here For More Historical Outlooks Of PolarityTE, Inc.
Previous Quarter Performance
PolarityTE, Inc. reported loss for the second quarter of $ 0.33 per share, from the revenue of $ 2.27 million. According to street consensus, PTE was expected to report 2Q20 loss of $ 0.38 per share from revenue of $ 0.83 million. The bottom line results beat street analysts by $ 0.05 or 13.16 percent, at the same time, top line results outshined analysts by $ 1.44 million or 173.49 percent.
Stock Performance
On Friday, shares of PolarityTE, Inc. has traded high as $ 1.01 and has cracked $ 0.89 on the downward trend, reaching $ 0.96 with volume of 876.20 thousand shares.
According to the previous trading day, closing price of $ 0.96, representing a 15.38 % increase from the 52 week low of $ 0.78 and a 80.43 % decrease over the 52 week high of $ 4.60.
The company has a market capital of $ 37.36 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
PolarityTE, Inc. will be hosting a conference call at 8:00 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.polarityte.com
PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services.
